Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial (VEnT)

University of Michigan Rogel Cancer Center

Status and phase: Enrolling; Phase 2

Conditions: Breast Ductal Carcinoma In Situ; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Localized Breast Carcinoma; Anatomic Stage I Breast Cancer AJCC v8

Treatments: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Fezolinetant; Procedure: Biospecimen Collection; Drug: Placebo Administration

Study type: Interventional

Funder types: Other

Identifiers

NCT06617455

NCI-2024-06543 (Registry Identifier)

UMCC 2024.059 (Other Identifier)

HUM00256706

Details and patient eligibility

About

This phase II trial tests how well fezolinetant works in improving vasomotor symptoms (VMS) in breast cancer patients taking endocrine therapy (ET). Anti-hormone treatments are effective for lowering the risk of breast cancer but can cause bothersome VMS, such as hot flashes and night sweats. Fezolinetant inhibits the activity of the neurokinin type 3 receptor and has shown activity against VMS in postmenopausal women. Taking fezolinetant may work well at improving VMS in breast cancer patients taking ET.

Enrollment: 36 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female subject aged ≥ 18 years
• Taking endocrine therapy (tamoxifen, anastrozole, exemestane, or letrozole) for adjuvant treatment of stage 1-3 breast cancer or for chemoprevention (breast ductal carcinoma in situ [DCIS] or high risk)
• Planning to take the same endocrine therapy for at least 10 weeks after study drug initiation
• Report 28 or more VMS episodes, at least some of which are severe or bothersome, during the 7-day screening period
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 x upper limit of normal (ULN) within 28 days prior to randomization
• Total bilirubin < 2 x ULN within 28 days prior to randomization
• Completion of chemotherapy, if given. Concurrent use of gonadotropin releasing hormone agonist (GnRHa) therapy, anti-HER2 therapy, bisphosphonate therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy, and abemaciclib therapy is permitted
• Patients receiving treatment with selective serotonin reuptake inhibitor (SSRIs), serotonin and norepinephrine reuptake inhibitor (SNRIs), gabapentinoids, clonidine, or oxybutynin must have been taking a stable dose for at least 30 days prior to enrollment if they plan to continue the drug during study participation, and willing to remain on the treatment for the duration of study participation. If they do not plan to take the medication during study participation, they should stop the medication at least 7 days before the start of the VMS screening period
• Patients taking over-the-counter supplements or herbal medications for treatment of VMS must stop the medication at least 7 days before the start of the VMS screening period
• Able to self-complete questionnaires in English
• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines
• For women of childbearing potential, participants must agree to use an effective contraceptive method during protocol therapy and for 3 months following completion of protocol therapy with details provided as a part of the consent process and must have a negative pregnancy test at screening. In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, and bilateral tubal ligation/occlusion

Exclusion criteria

• Metastatic breast cancer
• Prior treatment with fezolinetant
• Known severe renal disease (estimated glomerular filtration rate [eGFR] less than 30 mL/min/1.73 m^2)
• Known cirrhosis
• Pregnant or breast feeding, or plan to become pregnant during the study period or within 3 months of completing study medication
• Concomitant use of CYP1A2 inhibitors, including but not limited to fluvoxamine, ciprofloxacin, cimetidine, citalopram, and ribociclib
• Concomitant use of systemic or transdermal estrogen products
• Known allergy or hypersensitivity to fezolinetant or any of the excipients in the medication
• Unable to take oral medications
• Any medical condition that would interfere with the absorption of study medication. Prior gastric bypass is permitted
• Concurrent medical disease that could confound or interfere with evaluation of VMS
• Patients with a prior or concurrent malignancy whose natural history or treatment, in the opinion of the treating investigator, has the potential to interfere with the safety or efficacy assessment of the investigational regimen
• Patients who are participating concurrently in another interventional study (actually receiving a study medication) or participated in an interventional study within 30 days prior to screening or received any investigational drug within 30 days or within 5 half-lives prior to screening, whichever is longer

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

36 participants in 2 patient groups

Arm I (fezolinetant, placebo)

Experimental group

Description:

Patients receive fezolinetant PO QD for 28 days in the absence of unacceptable toxicity. Patients then go through a washout period and take no study medication for the next 14 days. Following the washout, patients receive placebo PO QD for 28 days in the absence of unacceptable toxicity. Patients undergo collection of blood samples throughout the study.

Treatment:

Drug: Placebo Administration

Procedure: Biospecimen Collection

Other: Questionnaire Administration

Drug: Fezolinetant

Other: Quality-of-Life Assessment

Arm II (placebo, fezolinetant)

Experimental group

Description:

Patients receive placebo PO QD for 28 days in the absence of unacceptable toxicity. Patients then go through a washout period and take no study medication for the next 14 days. Following the washout, patients receive fezolinetant PO QD for 28 days in the absence of unacceptable toxicity. Patients undergo collection of blood samples throughout the study.

Treatment:

Drug: Placebo Administration

Procedure: Biospecimen Collection

Other: Questionnaire Administration

Drug: Fezolinetant

Other: Quality-of-Life Assessment